The following poster presentations will be moderated: “Efficacy and safety of aprocitentan in patients with resistant ...

The poster will be presented at the American Heart Association ... TX45 is being evaluated in the APEX phase 2 clinical trial (NCT06616974) in patients with Group 2 Pulmonary Hypertension in Heart ...

Researchers provided recommendations for managing adverse events in patients with renal cell carcinoma receiving cabozantinib and nivolumab.

Tirupati: District Collector Dr S Venkateswar underlined the collective responsibility of healthcare officials and staff to ...

Quince Therapeutics (QNCX) announced the poster presentation at the 53rd Child Neurology ... hyperglycemia, hirsutism, or hypertension, were not observed. Three patients were discontinued from the ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

The exposure-response model is a nonlinear, mixed-effects Emax model that included repeated measurements of RPF for each subject in the study (>200 data points), resulting in a modeled E max (maximum ...

A new study highlights the importance of proper arm positioning during blood pressure measurement to avoid inaccurate readings and potential misdiagnosis of hypertension. Researchers found that ...

Minority groups are at a higher risk of developing pre-eclampsia, a high blood pressure condition, which can cause serious ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation .